



HAP Partners with Zerigo Health for a New Way to Deliver Dermatologic Care

We are expanding our population health programs to include dermatologic care options for providers through a new collaboration with Zerigo Health. The partnership introduces an in-home narrowband UVB (NB-UVB) phototherapy solution that helps providers manage psoriasis, eczema, and vitiligo patients more efficiently—while maintaining clinical oversight and quality standards.

Beginning December 1, Zerigo's FDA-cleared platform allows dermatologists and primary care providers to refer members for monitored light therapy delivered through a connected home device. Each treatment plan is defined by the prescribing Zerigo provider. Zerigo works in concert, providing dosing regimens and can provide a template or telehealth visit to complete any additional details. Zerigo's licensed Care Guides oversee ongoing treatment and ensure proper use, safety, and adherence.

Simplifying care delivery while strengthening connection

Zerigo's program is designed to complement, not complicate, clinical practice. The prescribing provider retains full authority over the prescription, dosing, and progression of care. Zerigo manages all patient-facing logistics: eligibility verification, onboarding, device setup, training, and adherence monitoring.

Providers can also start the prescription, and the patient can continue to receive care with the telehealth provider. Providers can opt in to receive secure, regular progress reports, giving them visibility into treatment adherence and outcomes without added administrative work. Zerigo's support model enables practices to expand access to guideline-based NB-UVB therapy without taking on the operational burden of managing at-home care.

A clinically proven, cost-effective alternative

Home phototherapy can be an effective next step for patients who haven't achieved adequate control with topical therapies. In similar health plan programs, more than 90% of participants reported measurable improvement and fewer than 3% progressed to biologics. These results align with the *JAMA Dermatology* LITE study (2024), which confirmed that home NB-UVB therapy achieves comparable outcomes to in-office treatment. For more information, please see the attached overview.

Two ways to engage with Zerigo

HAP providers can connect members to Zerigo in two simple ways:

1. **Member-initiated:** If a member expresses interest, Zerigo coordinates directly with the provider to facilitate prescription and onboarding.
2. **Provider-initiated:** Providers can refer eligible members directly through Zerigo's clinician portal.

A partner in better care

By partnering with Zerigo, HAP providers can offer patients a clinically validated, monitored therapy that extends the reach of their practice—improving outcomes, maintaining continuity of care, and preserving time for what matters most: the provider–patient relationship.

More information and referring patients

To refer a patient directly, contact support@zerigohealth.com. To learn more, visit zerigohealth.com/phototherapy-for-clinicians, and keep an eye on the HAP provider newsroom for more information including upcoming educational sessions.

Clinical Oversight Meets Patient Convenience: In-Home Phototherapy Done Right

The Problem

Phototherapy is a safe, effective and clinically proven treatment for certain chronic skin conditions. But until now, home phototherapy has been challenging to access.

Prior authorization hurdles, complex billing and prescription processes, frequent insurance denials and limited visibility into adherence - especially for at-home care, add to an already high administrative burden and delays in treatment.

Delays in care caused 68% of patients to experience worsened flares and 35% reported mental health impacts,¹ lowering their overall satisfaction with treatments, and providers.

Introducing: The Zerigo Skin Health Platform

- **FDA-Cleared, Handheld Device***: Narrowband ultraviolet light (UVB) used for at-home or on-the-go treatment, backed by clinical research.
- **Intelligent Software**: Remotely monitor, and engage patients and easily access treatment data - in real-time - to help provide interventions where and how patients need them.
- **1:1 Patient Engagement**: Licensed professionals support treatment and refer patients back to providers as-needed to extend your care beyond the clinic.
- **Dedicated Provider Support**: Reclaim your office hours with a dedicated team of staff to take on the administrative burdens of documentation, reporting, eligibility and prescription processing.

Why Providers Partner With Zerigo



Safe, Proven, Effective

80% of members achieved clear/almost clear skin at 12 weeks², with a 4.9/5 patient satisfaction rating³



High Adherence Rates

Real time patient communication & monitoring leads to 75% adherence⁴



Time to Treatment

<5 days from enrollment to starting treatment



Seamless Integration

No prior authorization needed. Zerigo works with your current systems

Key Success Metrics**, Psoriasis

Metric	Zerigo	TNF-α Inhibitors	Interleukin Inhibitors	PDE Inhibitors
Adherence	75%	50-63% ⁵	46-72% ⁵	62% ⁶
Clear/PASI-75 16 weeks ⁷	74-90%	40-80%	62-89%	30.8%
Common Adverse Events ⁸	Erythema <1%	53-58%	46-49%	41%
Retention (12-month) / Persistence ⁹	50%	32%	32%	30%

**These comparisons are based on extrapolations and/or published results from multiple studies, provided for informational purposes only, and have not been confirmed in head-to-head studies. Treatment outcomes/experiences vary.

*Zerigo Health's ultraviolet-light-emitting medical device is intended for use in localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). The device can be used at home or in a physician's office. Individual results may vary. U.S. federal law restricts this device to sale by or on the order of a physician.



Contact us today to learn how you can grow your practice with Zerigo

1. Begolka WS, Loiseau AR, Johnson JK, Guadalupe M, Thibau I. Frequency and Wait Times for Acute Care Needs in Outpatient Care Settings: A Survey – Study of Patients with Atopic Dermatitis. National Eczema Association; Novato, CA. Member self-reported skin clearance, psoriasis, 2018 - 2024
2. Member self-reported skin clearance, psoriasis, 2018-2024
3. Member self-reported satisfaction with Zerigo Skin Health Platform
4. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis – PMC <https://pmc.ncbi.nlm.nih.gov/articles/PMC8953925/>
5. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic – PMC <https://pubmed.ncbi.nlm.nih.gov/36111111/>
6. Wu JJ, Feldman SR, Guillemin I, et al. Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatol. 2024;160(12):1320-1328. doi:10.1001/jamadermatol.2024.2877
7. Study Details | Light Treatment Effectiveness (LITE) Study | ClinicalTrials.gov
8. Full article: Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies